The U.S. FDA published a draft guidance for hydrogen peroxide-based contact lens care products (HPCPs), which up until 1997 were seen as class III products requiring a PMA. However, this draft is a response to an increasing number of adverse events associated with these products, a problem that was the subject of a 2017 FDA advisory hearing.